Although SGLT-2 inhibitors and GLP-1 agonists show pharmacological differences in mechanism of action (inhibiting the reabsorption of renal glucose or stimulating insulin secretion, respectively) [1,8], they effectively reduce glucose levels, cardiovascular complications, and even mortality in people with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.